Title : Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.

Pub. Date : 2016 Aug 2

PMID : 27480131






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. Eflornithine ornithine decarboxylase 1 Homo sapiens
2 Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. Eflornithine ornithine decarboxylase 1 Homo sapiens
3 Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. Eflornithine ornithine decarboxylase 1 Homo sapiens
4 Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. Eflornithine ornithine decarboxylase 1 Homo sapiens